Compare Logitech International SA (LOGI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Moderna, Inc. — how do they compare? Logitech International SA trades at $104.56 (market cap $14.65B), while Moderna, Inc. trades at $60.12 (market cap $23.60B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Logitech International SA pays a 1.67% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| LOGI | MRNA | |
|---|---|---|
Market Cap | $14.65B | $23.60B |
Sector | Technology | Health |
52-Week High | $126.69 | $81.80 |
52-Week Low | $85.84 | $22.36 |
Enterprise Value | $13.00B | $19.70B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.83, down 0.98% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals including a 14.69% net margin and consistent earnings beats. Recent product launches like the G3 Series and Spotlight 2 presenter highlight innovation, while a partnership with Call of Duty: Modern Warfare 4 boosts gaming segment prospects. Cash flow trends show operational strength with 2025 operating cash flow at $842.56M.
The stock offers upside to the $113 consensus price target, driven by B2B and AI product expansion, but faces risks from competitive pressures and reliance on consumer spending. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid valuation metrics like a P/E of 21.43.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
